Mesenchymal stromal cell chondrogenesis under ALK1/2/3-specific BMP inhibition: a revision of the prohypertrophic signalling network concept

• Published in: Stem cell research & therapy Vol. 15; no. 1; p. 98
• Main Authors: Diederichs, Solvig, Dreher, Simon I, Nüesch, Sarah Anna, Schmidt, Sven, Merle, Christian, Richter, Wiltrud
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 05.04.2024; BioMed Central; BMC
• Subjects: ALK2; ALK3; Alkaline phosphatase; Animals; Biotechnology industry; Bone growth; Bone implants; Bone marrow; Bone morphogenetic proteins; Cartilage; Cells, Cultured; Chondrocytes - metabolism; Chondrogenesis; Collagen; Genes; Glucose; Growth factors; Hedgehog protein; Hedgehog Proteins - genetics; Humans; Hypertrophy; Hypertrophy - metabolism; Immunodeficiency; Kinases; Mesenchymal stem cells; Mesenchymal Stem Cells - metabolism; Mice; Mineralization; mRNA; Osteogenesis; Parathyroid hormone; Parathyroid hormone-related protein; Parathyroid Hormone-Related Protein - pharmacology; Penicillin; Phosphatases; Proteins; RNA; Solvents; Stem cells; Stromal cells; Surgery; TGF-β; Transforming Growth Factor beta - metabolism; Transforming growth factor-b; Transforming growth factors; Wnt protein; United States; Germany; United States > US; Switzerland; Cartilage; In vivo; BMP; TGF-β; ALK4; ALK5; Bone; ALK2; Chondrogenesis; PTHrP; ALK3; Hypertrophy
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-024-03710-7

In vitro chondrogenesis of mesenchymal stromal cells (MSCs) driven by the essential chondro-inducer transforming growth factor (TGF)-β is instable and yields undesired hypertrophic cartilage predisposed to bone formation in vivo. TGF-β can non-canonically activate bone morphogenetic protein-associated ALK1/2/3 receptors. These have been accused of driving hypertrophic MSC misdifferentiation, but data remained conflicting. We here tested the antihypertrophic capacity of two highly specific ALK1/2/3 inhibitors - compound A (CompA) and LDN-212854 (LDN21) - in order to reveal potential prohypertrophic contributions of these BMP/non-canonical TGF-β receptors during MSC in vitro chondrogenesis. Standard chondrogenic pellet cultures of human bone marrow-derived MSCs were treated with TGF-β and CompA (500 nM) or LDN21 (500 nM). Daily 6-hour pulses of parathyroid hormone-related peptide (PTHrP[1-34], 2.5 nM, from day 7) served as potent antihypertrophic control treatment. Day 28 samples were subcutaneously implanted into immunodeficient mice. All groups underwent strong chondrogenesis, but GAG/DNA deposition and ACAN expression were slightly but significantly reduced by ALK inhibition compared to solvent controls along with a mild decrease of the hypertrophy markers IHH-, SPP1-mRNA, and Alkaline phosphatase (ALP) activity. When corrected for the degree of chondrogenesis (COL2A1 expression), only pulsed PTHrP but not ALK1/2/3 inhibition qualified as antihypertrophic treatment. In vivo, all subcutaneous cartilaginous implants mineralized within 8 weeks, but PTHrP pretreated samples formed less bone and attracted significantly less haematopoietic marrow than ALK1/2/3 inhibitor groups. Overall, our data show that BMP-ALK1/2/3 inhibition cannot program mesenchymal stromal cells toward stable chondrogenesis. BMP-ALK1/2/3 signalling is no driver of hypertrophic MSC misdifferentiation and BMP receptor induction is not an adverse prohypertrophic side effect of TGF-β that leads to endochondral MSC misdifferentiation. Instead, the prohypertrophic network comprises misregulated PTHrP/hedgehog signalling and WNT activity, and a potential contribution of TGF-β-ALK4/5-mediated SMAD1/5/9 signalling should be further investigated to decide about its postulated prohypertrophic activity. This will help to successfully engineer cartilage replacement tissues from MSCs in vitro and translate these into clinical cartilage regenerative therapies.